Serra Ventures

TrackBill provides government affairs professionals with efficient mobile access to state and federal legislative information. It serves a diverse clientele, including professional service firms, corporations, and interest groups, enabling them to monitor bills relevant to their interests and track legislative activities. Users benefit from real-time alerts on key actions such as introductions, amendments, hearings, and votes. Additionally, TrackBill simplifies legislative reporting by allowing users to generate professional documents in Word, PDF, and Excel formats, as well as customizable, auto-updating website feeds. This functionality ensures that stakeholders remain informed about important legislative developments.

Ryvit develops an integration software that delivers seamless flow of data between premise and software used in the construction industry. The software integrates software application to enterprise resource product, customer relationship management, e-commerce, social apps, and specialty industry-specific system without exhausting development resources, empowering companies to experience the ease of intelligent integrations, driving profit through automation and optimization of the applications in use. Ryvit is headquartered in Saint Louis, Missouri.

TrackBill provides government affairs professionals with efficient mobile access to state and federal legislative information. It serves a diverse clientele, including professional service firms, corporations, and interest groups, enabling them to monitor bills relevant to their interests and track legislative activities. Users benefit from real-time alerts on key actions such as introductions, amendments, hearings, and votes. Additionally, TrackBill simplifies legislative reporting by allowing users to generate professional documents in Word, PDF, and Excel formats, as well as customizable, auto-updating website feeds. This functionality ensures that stakeholders remain informed about important legislative developments.

TrackBill provides government affairs professionals with efficient mobile access to state and federal legislative information. It serves a diverse clientele, including professional service firms, corporations, and interest groups, enabling them to monitor bills relevant to their interests and track legislative activities. Users benefit from real-time alerts on key actions such as introductions, amendments, hearings, and votes. Additionally, TrackBill simplifies legislative reporting by allowing users to generate professional documents in Word, PDF, and Excel formats, as well as customizable, auto-updating website feeds. This functionality ensures that stakeholders remain informed about important legislative developments.

Kypha Inc. is an early-stage life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, Kypha's flagship product, the COMP ACT System, is designed to enhance the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. The system offers a rapid and accurate assessment of inflammation levels in the body, facilitating timely clinical interventions by healthcare professionals. Established in 2009, Kypha has successfully raised over $3 million in private capital and leveraged federal grants to advance its diagnostic offerings towards FDA clearance and commercial launch. The company operates with a small core team, supported by a network of scientific advisors and clinical collaborators.

TrackBill provides government affairs professionals with efficient mobile access to state and federal legislative information. It serves a diverse clientele, including professional service firms, corporations, and interest groups, enabling them to monitor bills relevant to their interests and track legislative activities. Users benefit from real-time alerts on key actions such as introductions, amendments, hearings, and votes. Additionally, TrackBill simplifies legislative reporting by allowing users to generate professional documents in Word, PDF, and Excel formats, as well as customizable, auto-updating website feeds. This functionality ensures that stakeholders remain informed about important legislative developments.

OPER (ORDER. PAY. EARN. REDEEM.) is a central rewards app for restaurant diners. Our mobile food ordering, payment and rewards platform offers users 5% back on every food purchase while remaining free for both consumers and restaurants to participate.Anyone can download OPER's app for iPhone or Android, easily set up an account, add money to it, and place orders for delivery or pick-up. They can then pay using OPER's mobile app when dining in or carrying out and will be rewarded with 5% back on all restaurant purchases. The 5% reward can later be redeemed at any participating restaurant.

Adarza BioSystems is an early-stage medical diagnostics company developing a rapid and label-free biological assay platform for measuring clinical and point-of-care (POC) samples. In addition to performing sophisticated clinical tests within minutes, this technology potentially allowing hundreds of tests to be run simultaneously on a single chip. It was founded in 2008 and headquartered in St Louis, Missouri.

Kypha Inc. is an early-stage life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, Kypha's flagship product, the COMP ACT System, is designed to enhance the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. The system offers a rapid and accurate assessment of inflammation levels in the body, facilitating timely clinical interventions by healthcare professionals. Established in 2009, Kypha has successfully raised over $3 million in private capital and leveraged federal grants to advance its diagnostic offerings towards FDA clearance and commercial launch. The company operates with a small core team, supported by a network of scientific advisors and clinical collaborators.

OPER (ORDER. PAY. EARN. REDEEM.) is a central rewards app for restaurant diners. Our mobile food ordering, payment and rewards platform offers users 5% back on every food purchase while remaining free for both consumers and restaurants to participate.Anyone can download OPER's app for iPhone or Android, easily set up an account, add money to it, and place orders for delivery or pick-up. They can then pay using OPER's mobile app when dining in or carrying out and will be rewarded with 5% back on all restaurant purchases. The 5% reward can later be redeemed at any participating restaurant.

TrackBill provides government affairs professionals with efficient mobile access to state and federal legislative information. It serves a diverse clientele, including professional service firms, corporations, and interest groups, enabling them to monitor bills relevant to their interests and track legislative activities. Users benefit from real-time alerts on key actions such as introductions, amendments, hearings, and votes. Additionally, TrackBill simplifies legislative reporting by allowing users to generate professional documents in Word, PDF, and Excel formats, as well as customizable, auto-updating website feeds. This functionality ensures that stakeholders remain informed about important legislative developments.

Kypha Inc. is an early-stage life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, Kypha's flagship product, the COMP ACT System, is designed to enhance the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. The system offers a rapid and accurate assessment of inflammation levels in the body, facilitating timely clinical interventions by healthcare professionals. Established in 2009, Kypha has successfully raised over $3 million in private capital and leveraged federal grants to advance its diagnostic offerings towards FDA clearance and commercial launch. The company operates with a small core team, supported by a network of scientific advisors and clinical collaborators.

Adarza BioSystems is an early-stage medical diagnostics company developing a rapid and label-free biological assay platform for measuring clinical and point-of-care (POC) samples. In addition to performing sophisticated clinical tests within minutes, this technology potentially allowing hundreds of tests to be run simultaneously on a single chip. It was founded in 2008 and headquartered in St Louis, Missouri.

Kypha Inc. is an early-stage life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, Kypha's flagship product, the COMP ACT System, is designed to enhance the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. The system offers a rapid and accurate assessment of inflammation levels in the body, facilitating timely clinical interventions by healthcare professionals. Established in 2009, Kypha has successfully raised over $3 million in private capital and leveraged federal grants to advance its diagnostic offerings towards FDA clearance and commercial launch. The company operates with a small core team, supported by a network of scientific advisors and clinical collaborators.

Kypha Inc. is an early-stage life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, Kypha's flagship product, the COMP ACT System, is designed to enhance the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. The system offers a rapid and accurate assessment of inflammation levels in the body, facilitating timely clinical interventions by healthcare professionals. Established in 2009, Kypha has successfully raised over $3 million in private capital and leveraged federal grants to advance its diagnostic offerings towards FDA clearance and commercial launch. The company operates with a small core team, supported by a network of scientific advisors and clinical collaborators.

Tunespeak, LLC operates a musician-to-fan loyalty platform designed to engage users through various media interactions. Founded in 2011 and based in St. Louis, Missouri, the platform allows users to earn points by listening to music, watching videos, and sharing content with friends and followers. Additionally, it enables users' friends to accumulate points for a contestant based on their interactions with songs, pictures, and videos throughout contests or raffles. By fostering a deeper connection between musicians and their fans, Tunespeak enhances fan engagement and loyalty in the music industry.

Kypha Inc. is an early-stage life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, Kypha's flagship product, the COMP ACT System, is designed to enhance the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. The system offers a rapid and accurate assessment of inflammation levels in the body, facilitating timely clinical interventions by healthcare professionals. Established in 2009, Kypha has successfully raised over $3 million in private capital and leveraged federal grants to advance its diagnostic offerings towards FDA clearance and commercial launch. The company operates with a small core team, supported by a network of scientific advisors and clinical collaborators.

Kypha Inc. is an early-stage life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, Kypha's flagship product, the COMP ACT System, is designed to enhance the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. The system offers a rapid and accurate assessment of inflammation levels in the body, facilitating timely clinical interventions by healthcare professionals. Established in 2009, Kypha has successfully raised over $3 million in private capital and leveraged federal grants to advance its diagnostic offerings towards FDA clearance and commercial launch. The company operates with a small core team, supported by a network of scientific advisors and clinical collaborators.

Adarza BioSystems is an early-stage medical diagnostics company developing a rapid and label-free biological assay platform for measuring clinical and point-of-care (POC) samples. In addition to performing sophisticated clinical tests within minutes, this technology potentially allowing hundreds of tests to be run simultaneously on a single chip. It was founded in 2008 and headquartered in St Louis, Missouri.